BRUIN CLL-322 Trial Results Show Significant Superiority
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Success: The BRUIN CLL-322 trial demonstrated that the addition of Jaypirca to venetoclax and rituximab significantly reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia patients, potentially establishing a new standard of care.
- Patient Recruitment: The trial enrolled 639 relapsed or refractory patients, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the results are applicable to the modern CLL treatment landscape.
- Efficacy Assessment: With a median follow-up of 27.3 months, the progression-free survival (PFS) in the PVR arm was not reached, compared to 39.7 months in the VR arm, indicating the potential advantages of Jaypirca.
- Safety Analysis: The safety profile of BRUIN CLL-322 was consistent with known safety profiles, with similar rates of Grade ≥3 adverse events in the PVR and VR groups at 78.8% and 73.0%, respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1160.950
Low
950.00
Averages
1192
High
1500
Current: 1160.950
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Unveils Promising Data for New JAK2 Inhibitor in Myelofibrosis
- Clinical Trial Progress: Eli Lilly's AJX-101 study reveals promising safety and clinical activity for its novel type II JAK2 inhibitor AJ1-11095 in myelofibrosis patients who have failed type I JAK2 inhibitors, indicating significant therapeutic potential.
- Efficacy Metrics: Among 23 patients, 70% achieved a 35% reduction in spleen volume and the same percentage reported a 50% improvement in symptom burden at 12 weeks, suggesting the drug's efficacy surpasses existing treatments.
- Safety Assessment: The overall safety profile of AJ1-11095 is favorable, with no dose-limiting toxicities observed and 78% of patients remaining in the study during the dose escalation phase, indicating good tolerability and persistence.
- Future Research Directions: Lilly plans to further evaluate AJ1-11095 in high-risk polycythemia vera patients and those with myelofibrosis who have not yet received a JAK2 inhibitor, aiming to expand its clinical application and improve patient outcomes.
See More
BRUIN CLL-322 Study Shows Jaypirca Significantly Improves Outcomes in CLL Patients
- Clinical Trial Results: The BRUIN CLL-322 study demonstrated that the addition of Jaypirca to a regimen of venetoclax and rituximab reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia (CLL) patients, providing a more effective treatment option.
- Patient Recruitment: The study enrolled 639 patients with relapsed or refractory CLL, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the clinical applicability of the results in the current treatment landscape.
- Efficacy Assessment: At a median follow-up of 27.3 months, the primary endpoint of progression-free survival (PFS) was not reached in the Pirtobrutinib combination group, while the median PFS for the venetoclax and rituximab group was 39.7 months, highlighting the significant advantage of the combination therapy.
- Safety Analysis: The safety profile of BRUIN CLL-322 indicated that the addition of Pirtobrutinib did not significantly increase the incidence of adverse events, and treatment-related discontinuation rates were similar between the two groups, demonstrating good tolerability.
See More
BRUIN CLL-322 Study Shows Significant Superiority in CLL Treatment
- Clinical Trial Success: The BRUIN CLL-322 study demonstrates that the combination of Jaypirca (pirtobrutinib) with venetoclax and rituximab reduces the risk of disease progression or death by 45% (HR=0.55) compared to venetoclax and rituximab alone, providing a new treatment option for chronic lymphocytic leukemia (CLL) patients.
- Patient Recruitment: The study enrolled 639 patients with relapsed or refractory CLL, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the applicability of the results in the modern CLL treatment landscape and potentially establishing a new standard for second-line therapy.
- Efficacy Assessment: At a median follow-up of 27.3 months, the progression-free survival (PFS) in the PVR arm was not reached, while the VR arm reported 39.7 months, indicating significant efficacy of Jaypirca, particularly in high-risk patients who showed improved PFS.
- Safety Analysis: The safety profile of BRUIN CLL-322 was consistent with known safety profiles, with similar rates of Grade ≥3 adverse events between the PVR and VR groups (78.8% vs. 73.0%), demonstrating the good tolerability of Jaypirca and supporting its use in CLL treatment.
See More
BRUIN CLL-322 Trial Results Show Significant Superiority
- Clinical Trial Success: The BRUIN CLL-322 trial demonstrated that the addition of Jaypirca to venetoclax and rituximab significantly reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia patients, potentially establishing a new standard of care.
- Patient Recruitment: The trial enrolled 639 relapsed or refractory patients, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the results are applicable to the modern CLL treatment landscape.
- Efficacy Assessment: With a median follow-up of 27.3 months, the progression-free survival (PFS) in the PVR arm was not reached, compared to 39.7 months in the VR arm, indicating the potential advantages of Jaypirca.
- Safety Analysis: The safety profile of BRUIN CLL-322 was consistent with known safety profiles, with similar rates of Grade ≥3 adverse events in the PVR and VR groups at 78.8% and 73.0%, respectively.
See More
Eli Lilly Unveils Promising Data for New JAK2 Inhibitor AJ1-11095
- Clinical Trial Progress: Eli Lilly's AJX-101 study evaluated the first-in-class type II JAK2 inhibitor AJ1-11095 in 23 patients with myelofibrosis previously treated with type I JAK2 inhibitors, demonstrating a promising safety profile and potential new treatment options for resistant patients.
- Significant Efficacy Metrics: The study found that 70% of patients achieved at least a 35% reduction in spleen volume (SVR35) and 70% experienced over 50% symptom improvement (TSS50) at week 12, indicating AJ1-11095's potential to enhance patient quality of life.
- Variant Frequency Reduction: Among the 23 patients, 21 showed a decrease in driver mutation variant allele frequency (VAF), with 59% of patients achieving a VAF reduction of 20% or more and 35% achieving a reduction of 50% or more at week 24, highlighting AJ1-11095's unique advantage in tumor progression suppression.
- Manageable Safety Profile: The overall safety of AJ1-11095 was manageable with no dose-limiting toxicities observed, and 78% of patients remain in the study, with common adverse events including anemia and dysgeusia, demonstrating the drug's feasibility in clinical applications.
See More
Future Outlook for Obesity Drugs Market
- Intensifying Market Competition: At the conference in New Orleans, Eli Lilly and Novo Nordisk showcased their GLP-1 drugs, with Novo's Wegovy prescriptions exceeding 3 million within five months of launch, indicating that oral medications are attracting more consumers and could reshape the weight loss drug market.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data, and if their GLP-1 drugs succeed in Phase 3 trials, they are expected to hit the market by 2029, further enriching market options and intensifying competition.
- Innovative Administration Methods: Pfizer's new drug shows potential for monthly administration, which could be more convenient than current weekly injections, while Amgen is testing a drug that could be administered monthly or quarterly, aiming to enhance patient adherence to treatment.
- Future Market Outlook: With approximately 2.5 billion people globally classified as overweight and 890 million as obese, the competition will intensify as new drugs continue to emerge, while Lilly and Novo are also working to improve insurance coverage for GLP-1 drugs, which is expected to attract more patients.
See More
Eli Lilly Unveils Promising Data for New JAK2 Inhibitor in Myelofibrosis
- Clinical Trial Progress: Eli Lilly's AJX-101 study reveals promising safety and clinical activity for its novel type II JAK2 inhibitor AJ1-11095 in myelofibrosis patients who have failed type I JAK2 inhibitors, indicating significant therapeutic potential.
- Efficacy Metrics: Among 23 patients, 70% achieved a 35% reduction in spleen volume and the same percentage reported a 50% improvement in symptom burden at 12 weeks, suggesting the drug's efficacy surpasses existing treatments.
- Safety Assessment: The overall safety profile of AJ1-11095 is favorable, with no dose-limiting toxicities observed and 78% of patients remaining in the study during the dose escalation phase, indicating good tolerability and persistence.
- Future Research Directions: Lilly plans to further evaluate AJ1-11095 in high-risk polycythemia vera patients and those with myelofibrosis who have not yet received a JAK2 inhibitor, aiming to expand its clinical application and improve patient outcomes.
See More
BRUIN CLL-322 Study Shows Jaypirca Significantly Improves Outcomes in CLL Patients
- Clinical Trial Results: The BRUIN CLL-322 study demonstrated that the addition of Jaypirca to a regimen of venetoclax and rituximab reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia (CLL) patients, providing a more effective treatment option.
- Patient Recruitment: The study enrolled 639 patients with relapsed or refractory CLL, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the clinical applicability of the results in the current treatment landscape.
- Efficacy Assessment: At a median follow-up of 27.3 months, the primary endpoint of progression-free survival (PFS) was not reached in the Pirtobrutinib combination group, while the median PFS for the venetoclax and rituximab group was 39.7 months, highlighting the significant advantage of the combination therapy.
- Safety Analysis: The safety profile of BRUIN CLL-322 indicated that the addition of Pirtobrutinib did not significantly increase the incidence of adverse events, and treatment-related discontinuation rates were similar between the two groups, demonstrating good tolerability.
See More
BRUIN CLL-322 Study Shows Significant Superiority in CLL Treatment
- Clinical Trial Success: The BRUIN CLL-322 study demonstrates that the combination of Jaypirca (pirtobrutinib) with venetoclax and rituximab reduces the risk of disease progression or death by 45% (HR=0.55) compared to venetoclax and rituximab alone, providing a new treatment option for chronic lymphocytic leukemia (CLL) patients.
- Patient Recruitment: The study enrolled 639 patients with relapsed or refractory CLL, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the applicability of the results in the modern CLL treatment landscape and potentially establishing a new standard for second-line therapy.
- Efficacy Assessment: At a median follow-up of 27.3 months, the progression-free survival (PFS) in the PVR arm was not reached, while the VR arm reported 39.7 months, indicating significant efficacy of Jaypirca, particularly in high-risk patients who showed improved PFS.
- Safety Analysis: The safety profile of BRUIN CLL-322 was consistent with known safety profiles, with similar rates of Grade ≥3 adverse events between the PVR and VR groups (78.8% vs. 73.0%), demonstrating the good tolerability of Jaypirca and supporting its use in CLL treatment.
See More
BRUIN CLL-322 Trial Results Show Significant Superiority
- Clinical Trial Success: The BRUIN CLL-322 trial demonstrated that the addition of Jaypirca to venetoclax and rituximab significantly reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia patients, potentially establishing a new standard of care.
- Patient Recruitment: The trial enrolled 639 relapsed or refractory patients, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the results are applicable to the modern CLL treatment landscape.
- Efficacy Assessment: With a median follow-up of 27.3 months, the progression-free survival (PFS) in the PVR arm was not reached, compared to 39.7 months in the VR arm, indicating the potential advantages of Jaypirca.
- Safety Analysis: The safety profile of BRUIN CLL-322 was consistent with known safety profiles, with similar rates of Grade ≥3 adverse events in the PVR and VR groups at 78.8% and 73.0%, respectively.
See More
Eli Lilly Unveils Promising Data for New JAK2 Inhibitor AJ1-11095
- Clinical Trial Progress: Eli Lilly's AJX-101 study evaluated the first-in-class type II JAK2 inhibitor AJ1-11095 in 23 patients with myelofibrosis previously treated with type I JAK2 inhibitors, demonstrating a promising safety profile and potential new treatment options for resistant patients.
- Significant Efficacy Metrics: The study found that 70% of patients achieved at least a 35% reduction in spleen volume (SVR35) and 70% experienced over 50% symptom improvement (TSS50) at week 12, indicating AJ1-11095's potential to enhance patient quality of life.
- Variant Frequency Reduction: Among the 23 patients, 21 showed a decrease in driver mutation variant allele frequency (VAF), with 59% of patients achieving a VAF reduction of 20% or more and 35% achieving a reduction of 50% or more at week 24, highlighting AJ1-11095's unique advantage in tumor progression suppression.
- Manageable Safety Profile: The overall safety of AJ1-11095 was manageable with no dose-limiting toxicities observed, and 78% of patients remain in the study, with common adverse events including anemia and dysgeusia, demonstrating the drug's feasibility in clinical applications.
See More
Future Outlook for Obesity Drugs Market
- Intensifying Market Competition: At the conference in New Orleans, Eli Lilly and Novo Nordisk showcased their GLP-1 drugs, with Novo's Wegovy prescriptions exceeding 3 million within five months of launch, indicating that oral medications are attracting more consumers and could reshape the weight loss drug market.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data, and if their GLP-1 drugs succeed in Phase 3 trials, they are expected to hit the market by 2029, further enriching market options and intensifying competition.
- Innovative Administration Methods: Pfizer's new drug shows potential for monthly administration, which could be more convenient than current weekly injections, while Amgen is testing a drug that could be administered monthly or quarterly, aiming to enhance patient adherence to treatment.
- Future Market Outlook: With approximately 2.5 billion people globally classified as overweight and 890 million as obese, the competition will intensify as new drugs continue to emerge, while Lilly and Novo are also working to improve insurance coverage for GLP-1 drugs, which is expected to attract more patients.
See More
